During the 1990s, interest in the effects of growth hormone deficiency (GHD) in adults increased, and several studies were performed to evaluate the effects of growth hormone (GH) substitution therapy in these patients. Because adults with GHD have reduced bone mineral density (BMD) and an increased risk of fractures, the effects of GH replacement therapy on bone metabolism have been evaluated in long-term studies. A universal finding is that the serum and urinary levels of biochemical bone markers increase during GH substitution therapy, and these increases are dose dependent. After years of GH substitution therapy, the levels of biochemical bone markers remain elevated, according to some studies, whereas other studies report that these levels return to baseline. BMD of the spine, hip and forearm increase after 18–24 months of treatment. Bone mineral content (BMC) increases to a greater extent than BMD, because the areal projection of bone also increases. This difference could be caused by increased periosteal bone formation, but a measurement artefact resulting from the use of dual-energy X-ray absorptiometry cannot be excluded as a possible explanation. One study of GH-deficient adults found that, after 33 months of GH treatment, BMD and BMC increased to a greater extent in men with GHD than in women. There is also a gender difference in the increases in serum levels of insulin-like growth factor I and biochemical bone markers during GH treatment. The reason for these findings is unknown, and the role of sex steroids in determining the response to GH therapy remains to be fully elucidated.

Keywords:
Biochemical bone markers, Bone mineral density, Growth hormone, Growth hormone deficiency
1.
Johansson AG, Burman P, Westermark K, Ljunghall S: The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med 1992;232:447–452.
2.
Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM: Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669–674.
3.
Kaufman J-M, Taelman P, Vermeulen A, Vandeweghe M: Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118–123.
4.
de Boer H, Blok GJ, van Lingen A, Teule GJJ, Lips P, van der Veen EA: Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9:1319–1326.
5.
Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson B-Å, Strasburger CJ: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82–88.
6.
Rosén T, Hansson T, Granhed H, Szucs J, Bengtsson B-Å: Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:201–206.
7.
Wüster C, Slenczka E, Ziegler R: Increased prevalence of osteoporosis and arteriosclerosis in patients with conventionally substituted pituitary insufficiency: Is there a need for additional growth hormone substitution? Klin Wochenschr 1991;69:769–773.
8.
Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson B-Å: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997;137:240–245.
9.
Kassem M, Blum W, Risteli J, Mosekilde L, Eriksen EF: Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int 1993;52:222–226.
10.
Mochizuki H, Hakeda Y, Wakatsuki N, Usui N, Akashi S, Sato T, Tanaka K, Kumegawa M: Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 1992;131:1075–1080.
11.
Canalis E: Effect of insulin-like growth factor I on DNA and protein synthesis in cultured rat calvariae. J Clin Invest 1980;66:709–719.
12.
Hock JM, Centrella M, Canalis E: Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 1988;122:254–260.
13.
Delmas PD: Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990;19:1–18.
14.
Hyer SL, Rodin DA, Tobias JH, Leiper A, Nussey SS: Growth hormone deficiency during puberty reduces adult bone mineral density. Arch Dis Child 1992;67:1472–1474.
15.
Nielsen HK, Jorgensen JOL, Brixen K, Christiansen JS: Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: Dose-response studies with biosynthetic human GH. Calcif Tissue Int 1991;48:82–87.
16.
Johannsen JS, Pedersen SA, Jorgensen JOL, Riis BJ, Christiansen C, Christiansen JS, Skakkebaek NE: Effects of growth hormone on bone GLA protein in GH-deficient adults. J Clin Endocrinol Metab 1990;70:916–919.
17.
Bravenboer N, Holzmann P, de Boer H, Blok GJ, Lips P: Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 1996;18:551–557.
18.
Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A: A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990;5:609–618.
19.
Johansson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall S: Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996;81:44–48.
20.
Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G: Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993;122:37–45.
21.
Johansson AG, Edén Engström B, Ljunghall S, Karlsson FA, Burman P: Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999;84:2002–2007.
22.
Johannsson G, Rosén T, Bosaeus I, Sjoström L, Bengtsson B-Å: Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81:2865–2873.
23.
Baum HBA, Biller BMK, Finkelstein JS, Baker Cannistraro K, Oppenhein DS, Schoenfeld DA, Hoskins Michel T, Wittink H, Klibanski A: Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125:883–890.
24.
Valimaki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E: Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1999;140:545–554.
25.
Jensen LT, Jorgensen JOL, Risteli J, Christiansen JS, Lorenzen I: Type I and III procollagen propeptides in growth hormone-deficient patients: Effects of increasing doses of GH. Acta Endocrinol (Copenh) 1991;124:278–282.
26.
Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR: Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 1992;36:45–52.
27.
Binnerts A, Swart GR, Wilson JHP, Hoogerbrugge N, Pols HA, Birkenhager JC, Lamberts SW: The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as body composition. Clin Endocrinol (Oxf) 1992;37:79–87.
28.
Vandeweghe M, Taelman P, Kaufman JM: Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf) 1993;39:409–415.
29.
Janssen YJ, Hamdy NA, Frolich M, Roelfsema F: Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:2143–2148.
30.
Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G: Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J Endocrinol Invest 1999;22:333–339.
31.
Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J: Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 1998;48:561–568.
32.
Holmes SJ, Whitehouse RW, Economou G, O’Halloran DJ, Adams JE, Shalet SM: Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clin Endocrinol (Oxf) 1995;42:3–7.
33.
Rahim A, Holmes SJ, Adams JE, Shalet SM: Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin Endocrinol (Oxf) 1998;48:463–469.
34.
Finkenstedt G, Gasser RW, Höfle G, Watfah C, Fridrich L: Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: Results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol 1997;136:282–289.
35.
O’Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM: Increased bone density after recombinant human growth hormone therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993;76:1344–1348.
36.
Juul A, Pedersen SA, Sorensen S, Winkler K, Jorgensen JOL, Christiansen JS, Skakkebaek NE: Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol 1994;131:41–49.
37.
Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM: Effects of growth hormone replacement on bone mass in adults with adult-onset growth hormone deficiency. Clin Endocrinol (Oxf) 1995;42:627–633.
38.
Amato G, Izzo G, La Montagna G, Bellastella A: Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol (Oxf) 1996;45:27–32.
39.
Degerblad M, Elgindy N, Hall K, Sjöberg HE, Thorén M: Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol (Copenh) 1992;126:387–393.
40.
Rosén T, Johannsson G, Bengtsson B-Å: Consequences of growth hormone deficiency in adults, and effects of growth hormone replacement therapy. Acta Paediatr 1994;399(suppl):21–24.
41.
ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA: Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999;84:2373–2380.
42.
Thorén M, Soop M, Degerblad M, Saaf M: Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adult growth hormone deficiency. Acta Endocrinol (Copenh) 1993;128(suppl 2):41–43.
43.
Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J: The effect of low dose recombinant human growth hormone replacement on indices of bone remodelling and bone mineral density in hypopituitary growth hormone-deficient adults. Endocrinol Metab 1996;3:55–61.
44.
Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D: The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998;83:107–116.
45.
Degerblad M, Bengtsson B-Å, Bramnert M, Johnell O, Manhem P, Rosén T, Thorén M: Reduced bone mineral density in adults with growth hormone (GH) deficiency: Increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 1995;133:180–188.
46.
Bravenboer N, Holzmann P, de Boer H, Roos JC, van der Veen EA, Lips P: The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab 1997;82:1818–1822.
47.
Edén Engström B, Karlsson FA, Wide L: Marked gender differences in ambulatory morning growth hormone values in young adults. Clin Chem 1998;44:1289–1295.
48.
Jansson J-O, Edén S, Isaksson O: Sexual dimorphism in the control of growth hormone secretion. Endo Rev 1985;6:1128–1150.
49.
Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744–752.
50.
Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA: Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997;82:550–555.
51.
Cook DM, Ludlam WH, Cook MB: Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 1999;84:3956–3960.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.